Literature DB >> 23470789

Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema.

A Koytak1, M Altinisik, E Sogutlu Sari, O Artunay, J C Umurhan Akkan, K Tuncer.   

Abstract

PURPOSE: The aim of this study is to compare the therapeutic effect of a single intravitreal bevacizumab (IVB) injection in eyes with diabetic macular oedema (DMO) of different patterns determined by optical coherence tomography (OCT).
METHODS: Medical records of patients who had a single IVB injection for DMO were analysed retrospectively. Eyes with a clinically significant DMO and a central foveal thickness (CFT) of 250 μm or more determined by OCT were included in the analysis. Best-corrected visual acuity (BCVA), CFT and total macular volume values before and after the injection were recorded. Eyes were divided into sponge-like diffuse retinal thickening (DRT), cystoid macular oedema (CMO) and serous retinal detachment (SRD) groups according to the morphology on OCT.
RESULTS: A total of 92 eyes (42 with DRT, 31 with CMO and 19 with SRD) were included in the study. There was no statistically significant variation between three groups regarding the change in BCVA (P=0.695). CMO and SRD groups had greater reductions in their mean CFT, and the amount of reduction showed statistically significant variation between three groups (P=0.048). However, no statistically significant difference was found between groups in terms of percentage of change in CFT (P=0.278).
CONCLUSION: CMO and SRD subtypes are associated with a greater reduction in the CFT than the DRT subtype. Although the change in BCVA was not significantly different between groups, the DRT group showed markedly better visual improvement in proportion to the decrease in CFT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23470789      PMCID: PMC3682346          DOI: 10.1038/eye.2013.17

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  19 in total

1.  Features of optical coherence tomography are predictive of visual outcomes after intravitreal bevacizumab injection for diabetic macular edema.

Authors:  Mi In Roh; Ji Hyun Kim; Oh Woong Kwon
Journal:  Ophthalmologica       Date:  2010-05-04       Impact factor: 3.250

2.  Visual outcome after intravitreal triamcinolone acetonide depends on optical coherence tomographic patterns in patients with diffuse diabetic macular edema.

Authors:  Masahiko Shimura; Kanako Yasuda; Toru Nakazawa; Yoshio Hirano; Taiji Sakamoto; Yuichiro Ogura; Takashi Shiono
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

3.  Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier.

Authors:  B Sander; M Larsen; B Moldow; H Lund-Andersen
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-02       Impact factor: 4.799

4.  Topography of diabetic macular edema with optical coherence tomography.

Authors:  M R Hee; C A Puliafito; J S Duker; E Reichel; J G Coker; J R Wilkins; J S Schuman; E A Swanson; J G Fujimoto
Journal:  Ophthalmology       Date:  1998-02       Impact factor: 12.079

5.  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1985-12

6.  Pathology of human cystoid macular edema.

Authors:  M Yanoff; B S Fine; A J Brucker; R C Eagle
Journal:  Surv Ophthalmol       Date:  1984-05       Impact factor: 6.048

7.  Macular edema and cystoid macular edema.

Authors:  B S Fine; A J Brucker
Journal:  Am J Ophthalmol       Date:  1981-10       Impact factor: 5.258

8.  Clinicopathologic study of blood-retinal barrier in experimental diabetes mellitus.

Authors:  M O Tso; J G Cunha-Vaz; C Y Shih; C W Jones
Journal:  Arch Ophthalmol       Date:  1980-11

9.  Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.

Authors:  J Fernando Arevalo; Juan G Sanchez; Lihteh Wu; Mauricio Maia; Arturo A Alezzandrini; Miguel Brito; Sergio Bonafonte; Silvio Lujan; Manuel Diaz-Llopis; Natalia Restrepo; Francisco J Rodríguez; Patricia Udaondo-Mirete
Journal:  Ophthalmology       Date:  2009-07-09       Impact factor: 12.079

10.  Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulation.

Authors:  N R Kim; Y J Kim; H S Chin; Y S Moon
Journal:  Br J Ophthalmol       Date:  2009-03-01       Impact factor: 4.638

View more
  14 in total

1.  Improvement of visual acuity based on optical coherence tomography patterns following intravitreal bevacizumab treatment in patients with diabetic macular edema.

Authors:  Haider R Cheema; Ahmed Al Habash; Essam Al-Askar
Journal:  Int J Ophthalmol       Date:  2014-04-18       Impact factor: 1.779

2.  Evaluation of systemic risk factors in different optical coherence tomographic patterns of diabetic macular edema.

Authors:  Durgul Acan; Eyyup Karahan; Nilufer Kocak; Suleyman Kaynak
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779

3.  Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.

Authors:  Yijun Hu; Qiaowei Wu; Baoyi Liu; Dan Cao; Xinran Dong; Liang Zhang; Tao Li; Xiaohong Yang; Honghua Yu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-09-16       Impact factor: 3.117

4.  Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales' Disease patients.

Authors:  Ponnalagu Murugeswari; Dhananjay Shukla; Ramasamy Kim; Perumalsamy Namperumalsamy; Alan W Stitt; Veerappan Muthukkaruppan
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

5.  Intravitreal bevacizumab injections for diabetic macular edema - predictors of response: a retrospective study.

Authors:  Lavnish Joshi; Asaf Bar; Oren Tomkins-Netzer; Satish Yaganti; Jiten Morarji; Panayiotis Vouzounis; Sophie Seguin-Greenstein; Simon R Taylor; Sue Lightman
Journal:  Clin Ophthalmol       Date:  2016-10-21

6.  Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy

Authors:  Seher Eraslan; Özlem Yıldırım; Özer Dursun; Erdem Dinç; Gülhan Orekici Temel
Journal:  Turk J Ophthalmol       Date:  2020-06-27

7.  Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.

Authors:  Mahmut Kaya; Eyyup Karahan; Taylan Ozturk; Nilufer Kocak; Suleyman Kaynak
Journal:  Korean J Ophthalmol       Date:  2018-08

8.  Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion.

Authors:  Emine Dogan; Ozkan Sever; Burcin Köklü Çakır; Erkan Celik
Journal:  Clin Ophthalmol       Date:  2018-08-17

9.  Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases.

Authors:  Yen-Po Chen; Ai-Ling Wu; Chih-Chun Chuang; San-Ni Chen
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

10.  Baseline SD-OCT characteristics of diabetic macular oedema patterns can predict morphological features and timing of recurrence in patients treated with dexamethasone intravitreal implants.

Authors:  Chiara M Eandi; Daniele De Geronimo; Daniela Giannini; Maria Sole Polito; Gian Marco Tosi; Giovanni Neri; Yannick Le Mer; Monica Varano; Mariacristina Parravano
Journal:  Acta Diabetol       Date:  2020-02-29       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.